Prevalence of low serum folate and vitamin B12 in an older Australian population

Victoria M. Flood  
University of Wollongong, vfllood@uow.edu.au

Wayne T. Smith  
University of Newcastle

Karen L. Webb  
University of Sydney

Elena Rochtchina  
University of Sydney

Valerie Anderson  
Westmead Hospital

See next page for additional authors

Publication Details

Prevalence of low serum folate and vitamin B12 in an older Australian population

Abstract
Objective: To examine the prevalence of low serum folate and vitamin B12, in association with elevated serum homocysteine, in a representative sample of older Australians. Methods: During 1997-2000, 3,508 persons aged 50+ years were examined in a population-based cohort study conducted in two postcodes, west of Sydney, Australia. Of these, 2,901 participants (82.7%) provided fasting blood for estimates of serum folate, vitamin B12 and total homocysteine. Results: Low serum B12 (<185 pmol/L) was found in 22.9% of participants and low serum folate (<6.8 nmol/L) in 2.3% of participants. Among those people with very low serum vitamin B12 (<125 pmol/L) and low serum folate, 51% had elevated homocysteine. Conclusions: Low serum levels of vitamin B12 and elevated serum homocysteine are relatively frequent in older Australians. Implications: Appropriate public health action should be considered to reduce the prevalence of low serum vitamin B12 and elevated homocysteine in older Australians.

Keywords
folate, vitamin, b12, older, prevalence, australian, low, population, serum

Disciplines
Arts and Humanities | Life Sciences | Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details

Authors

This journal article is available at Research Online: http://ro.uow.edu.au/hbspapers/319
Prevalence of low serum folate and vitamin B12 in an older Australian population

Abstract

Objective: To examine the prevalence of low serum folate and vitamin B12, in association with elevated serum homocysteine, in a representative sample of older Australians.

Methods: During 1997-2000, 3,508 persons aged 50+ years were examined in a population-based cohort study conducted in two postcodes, west of Sydney, Australia. Of these, 2,901 participants (82.7%) provided fasting blood for estimates of serum folate, vitamin B12 and total homocysteine.

Results: Low serum B12 (<185 pmol/L) was found in 22.9% of participants and low serum folate (<6.8 nmol/L) in 2.3% of participants. Among those people with very low serum vitamin B12 (<125 pmol/L) and low serum folate, 51% had elevated homocysteine.

Conclusions: Low serum levels of vitamin B12 and elevated serum homocysteine are relatively frequent in older Australians.

Implications: Appropriate public health action should be considered to reduce the prevalence of low serum vitamin B12 and elevated homocysteine in older Australians.

(Aust N Z J Public Health 2006; 30: 38-41)

Submitted: April 2005
Revision requested: June 2005
Accepted: August 2005

Correspondence to:
Professor Paul Mitchell, Centre for Vision Research, Westmead Hospital, New South Wales 2145. Fax: (02) 9845 8345; e-mail: paul_mitchell@wmi.usyd.edu.au
child-bearing age, since numerous studies have shown that higher folate intake can prevent neonatal neural tube defects. However, to determine the public health impact of folate fortification on middle aged and older people, reliable prevalence estimates for both vitamin B12 and folate deficiency are required. Recent studies have been reported from United Kingdom, the Netherlands, United States of America and New Zealand, with prevalence estimates for vitamin B12 deficiency ranging from 10-40%, depending on the method and cut-points used to determine deficiency. No population-based studies of blood levels for folate, vitamin B12 and homocysteine have been conducted in Australia.

We report data from a representative population of older Australians to examine the prevalence of low serum folate and vitamin B12 and their effects on serum homocysteine.

Methods

Study population

A population cohort of 3,654 residents aged 49 years or older, living in two postcode areas of the Blue Mountains region, west of Sydney, was surveyed during 1992-94 for the Blue Mountains Eye Study (BMES1). The current study included 2,332 survivors from the cohort seen in BMES1 (response 75%, after excluding deaths) and a further 1,174 age-eligible residents not examined in BMES1 who had moved to the area over the five-year period since BMES1. These subjects had an age range of 50-98 years and were examined during the period 1997-2000, with an overall response of 83%. Of 3,508 total participants in the second cross-section, 2,963 provided blood for analysis (84.5%). This population had an age range of 83%. Of 3,508 total participants in the second cross-section, 2,963 provided blood for analysis (84.5%). This population had an age range of 83%. Of 3,508 total participants in the second cross-section, 2,963 provided blood for analysis (84.5%). This population had an age range of 83%

Blood assays

Participants returned for fasting blood tests following their eye examinations, with biochemical estimations conducted at the Institute of Clinical Pathology and Medical Research (ICPMR) at Westmead Hospital. Serum vitamin B12, folate and red cell folate assays were performed using the competitive-binding assay method, conducted on a Beckman-Access analyzer. Total serum homocysteine assays were derived using a fluorescence polarisation immunoassay method on an IMx Analyzer. Serum folate, vitamin B12 and serum homocysteine were performed in assays for 2,901 subjects, while red cell folate assays were performed on a subsample of available fresh red cells (n=1,460). More details about the laboratory methods used are available on request.

Because functional folate and vitamin B12 deficiency are not well defined, and the vitamin B12 cut-off for the diagnosis of deficiency in older people may need to be increased, we applied a number of cut-points for serum vitamin B12: <125 pmol/L (ICPMR laboratory guide), 125-<185 pmol/L, 185-<220 pmol/L and ≥220 pmol/L. Serum folate cut-points were: <6.8 nmol/L (ICPMR lab guide), 6.8-<11 nmol/L and ≥11 nmol/L. Cut-points for red cell folate were: <370 nmol/L (ICPMR lab guide), 370-<513 nmol/L and ≥513 nmol/L. Red cell folate was included because it may be a better measure of long-term folate intake than serum folate.

Statistical analyses

The proportion of persons with serum folate, serum vitamin B12 and red cell folate at various cut-points were estimated and those with elevated serum homocysteine (>15 μmol/L) are indicated by each category. Significant differences between genders were calculated using z-ratios. Figures present the proportion of people considered as likely to be deficient or at risk of deficiency in folate (red cell folate) or vitamin B12, by gender and age categories (p for trend calculated using the Mantel-Haenszel chi-square statistic). The maximum number for each table and figure

### Table 1: Prevalence of various cut-points for low serum vitamin B12, serum folate and red cell folate, and proportion who had elevated serum homocysteine (>15 μmol/L) in 2,901 older Australians.

<table>
<thead>
<tr>
<th>Variable</th>
<th>n (%)</th>
<th>Homocysteine &gt;15 μmol/L (n, % of those in blood category)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Women</td>
</tr>
<tr>
<td>Serum vitamin B12 (pmol/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. very low&lt;125</td>
<td>184 (6.3)</td>
<td>101 (6.1)</td>
</tr>
<tr>
<td>2. low125&lt;185</td>
<td>481 (16.6)</td>
<td>263 (15.9)</td>
</tr>
<tr>
<td>3. moderately low185&lt;220</td>
<td>359 (12.4)</td>
<td>178 (10.8)</td>
</tr>
<tr>
<td>4. normal ≥220</td>
<td>1,877 (64.7)</td>
<td>1,113 (67.2)</td>
</tr>
<tr>
<td>Serum folate (nmol/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. very low&lt;6.8</td>
<td>66 (2.3)</td>
<td>32 (1.9)</td>
</tr>
<tr>
<td>2. moderately low6.8&lt;11</td>
<td>471 (16.2)</td>
<td>255 (15.4)</td>
</tr>
<tr>
<td>3. normal ≥11</td>
<td>2,364 (81.5)</td>
<td>1,367 (82.6)</td>
</tr>
<tr>
<td>Red cell folate (nmol/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. very low&lt;370</td>
<td>20 (1.4)</td>
<td>12 (1.5)</td>
</tr>
<tr>
<td>2. moderately low370&lt;513</td>
<td>82 (5.8)</td>
<td>51 (6.5)</td>
</tr>
<tr>
<td>3. normal ≥513</td>
<td>1,313 (92.8)</td>
<td>718 (91.9)</td>
</tr>
</tbody>
</table>

Notes:

(a) p for significant difference by gender <0.05 (calculated using the z-ratio for significance of difference between independent proportion).
(b) p for significant difference by gender <0.01.
is presented, so that subject number may vary between tables. All analyses used SAS version 8.0 (SAS Institute, Inc. Cary, NC). P-values <0.05 were considered statistically significant.

Results

Table 1 shows the prevalence of low B12 and folate using various cut-points. Very low levels of serum vitamin B12, indicating deficiency (<125 pmol/L) were observed in 6.3% of BMES participants (6.1% of women and 6.7% of men). Low serum vitamin B12 (<185 pmol/L) was present in 22.9% of persons (22.0% of women and 24.2% of men), and 35.3% when moderately low serum B12 level was defined as <220 pmol/L. Very low serum folate (<6.8 nmol/L) was present in only 2.3% of persons in this age range (2.0% of women and 2.7% of men), but 18.5% were low using the higher cut-point of <11.0 nmol/L. Based on red cell folate assays, 1.4% of persons (1.5% of women and 1.3% of men) had very low levels of folate, indicating a high likelihood of folate deficiency (<370 nmol/L) and 7.2% had moderately low folate levels (<513 nmol/L). In persons with very low serum vitamin B12 and very low serum folate, about 51% had elevated homocysteine levels. In persons with very low and moderately low red cell folate, approximately 65% and 45%, respectively, had elevated homocysteine levels. Men were more likely to have elevated serum homocysteine levels with very low concentrations of serum vitamin B12 and serum folate ($p$ for trend in men $=0.008$, $p$ for trend in women $=0.04$, respectively). Overall, elevated serum homocysteine (>15 µmol/L) was found in 16.7% of participants (20.8% men and 13.7% of women, $p=0.0001$) in this population.

The proportion of people with low serum vitamin B12 increased with age as shown in Figure 1 and this trend was more marked in men ($p$ for trend in men $\leq 0.0001$). Among persons aged 80 years or older, 9.5% of women and 13.6% of men had very low serum B12, indicating a high likelihood of vitamin B12 deficiency. Approximately 30% of men aged 70 years and over and women aged 80 years and over had low serum B12 values, and were thus at risk of vitamin B12 deficiency.

The prevalence of very low red cell folate increased with age for both women and men, and the trend was particularly marked for men ($p$ for trend in men $=0.0001$), with the prevalence increasing to 9.4% in men aged 80 years or older. Using a higher cut-point (<513 nmol/L), relatively similar proportions of older men and women were at risk of folate deficiency, rising with age to around 16% among persons aged 80 years or older.

Discussion

This study provides evidence that a relatively high proportion of older Australians have low vitamin B12 levels (22.9%). Although low blood folate levels were uncommon, the proportion with low levels of folate increased with age, up to 10% among males 80 years and over. In addition, about half of those with very low serum vitamin B12, very low serum folate and moderately low red cell folate demonstrated a likelihood of having a functional deficiency, as they had elevated serum homocysteine. Increased evidence suggests that the measurement of serum methylmalonic acid (MMA) and/or serum total homocysteine should be included in the tools to diagnose vitamin B12 or folate deficiency, especially in cases of borderline concentrations. MMA is a more expensive measure and therefore less practical to include in regular clinical assessments. Overall, we found an elevated serum homocysteine in a relatively high proportion (16.7%) of the study population. This is an important finding, not only in terms of the associated increased risk with vitamin B12 and folate deficiency, but because it is a possible independent risk factor for vascular disease.\(^3\)
In Australia, folate fortification of food is voluntary, and breakfast cereals are the main products fortified. In previous research, we examined the potential impact on folate intake in older people if folate fortification became mandatory in Australia. Under this scenario, our results showed that only 0.5% of the study population would be likely to consume levels greater than 1000 µg per day from synthetic folic acid, the intake considered by the Institute of Medicine (IOM) as the tolerable upper intake level. Concern has been expressed in the literature that mandatory folate fortification may adversely affect people with B12 deficiency by masking the deficiency, although this risk is considered very low if clinicians routinely diagnose B12 deficiency with appropriate tests, including serum B12 levels and homocysteine. Evidence concerning relevant clinical practice could not be located in the literature, but the results of a recent United States (US) study concerning relevant clinical practice could not be located in the literature. The prevalence of megaloblastic anaemia before and after intervention trial, Bjorkegren (2004) observed an improvement in not only haematological parameters but also neurological symptoms (indicative of folate deficiency), among older people receiving folate and B12 supplements who had been identified with low serum B12 and elevated homocysteine or MMA. Other studies have shown no or little improvement in clinical symptoms or health-related quality of life with lowering MMA or homocysteine. These studies, however, were conducted on younger adults.

This paper provides the first population-based data about the status of folate, vitamin B12 and homocysteine levels among older people in Australia. Of particular concern is the substantial pool of older people at risk of vitamin B12 deficiency and the prevalence of elevated serum homocysteine levels, for which evidence indicates is an independent risk factor for vascular disease. An understanding of the modifiable determinants of serum homocysteine and serum vitamin B12 will be important in determining future public health recommendations.

Acknowledgements

The authors would like to thank Dr Bridget Wilcken and Ms Helen Leung for assistance with laboratory analyses, and Professor Bruce Armstrong for useful comments on early drafts of data. The authors also thank the Institute of Clinical Pathology and Medical Research, Westmead Hospital, for its support. Sponsorship: Australian National Health and Medical Research Council, Kellogg’s Pty Ltd, Westmead Millennium Institute.

References


2006 VOL. 30 NO. 1 AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH 41